Genmab starts new cooperation phase with Janssen

Genmab A/S announced today that its collaboration partner, Janssen Biotech, Inc. ("Janssen") plans to start a new Phase III study of daratumumab in multiple myeloma. The study (MMY3008) will compare daratumumab in combination with lenalidomide and dexamethasone to lenalidomide and dexamethasone alone as front line treatment for patients who are not considered candidates for stem cell transplantation (SCT). The study is planned to start in the first half of 2015. The first Phase III study in front line multiple myeloma was announced in July and is expected to start towards the end of this year. Today's news is the fourth daratumumab Phase III study to be announced.

"This new study of daratumumab in front line multiple myeloma is part of the extensive development plan created under our collaboration with Janssen Biotech for our CD38 antibody daratumumab,",/em> said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.